Hua Medicine-B (02552) to Review FY2025 Results and Final Dividend Proposal on 26 March 2026

Bulletin Express

03/16

Hua Medicine-B (stock code: 02552) has scheduled a board meeting for 26 March 2026 (Thursday), according to a filing with The Stock Exchange of Hong Kong Limited dated 16 March 2026.

The agenda includes: 1. Approval of the audited financial results for the year ended 31 December 2025. 2. Consideration of a final dividend recommendation, if any. 3. Discussion of other routine corporate matters.

The board currently consists of three executive directors (Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang), one non-executive director (Mr. Robert Taylor Nelsen) and three independent non-executive directors (Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung).

The company will release its FY2025 results after board approval, providing shareholders with detailed financial information and any dividend decision.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1185329206"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185329206\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185329206?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185329206","market":"us","top_or_hot":-1,"title":"Hua Medicine-B (02552) to Review FY2025 Results and Final Dividend Proposal on 26 March 2026","media":"Bulletin Express","content":"<p>Hua Medicine-B (stock code: 02552) has scheduled a board meeting for 26 March 2026 (Thursday), according to a filing with The Stock Exchange of Hong Kong Limited dated 16 March 2026.</p>\n<p>The agenda includes:\n1. Approval of the audited financial results for the year ended 31 December 2025.\n2. Consideration of a final dividend recommendation, if any.\n3. Discussion of other routine corporate matters.</p>\n<p>The board currently consists of three executive directors (Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang), one non-executive director (Mr. Robert Taylor Nelsen) and three independent non-executive directors (Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung).</p>\n<p>The company will release its FY2025 results after board approval, providing shareholders with detailed financial information and any dividend decision.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hua Medicine-B (02552) to Review FY2025 Results and Final Dividend Proposal on 26 March 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHua Medicine-B (02552) to Review FY2025 Results and Final Dividend Proposal on 26 March 2026\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-16 16:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Hua Medicine-B (stock code: 02552) has scheduled a board meeting for 26 March 2026 (Thursday), according to a filing with The Stock Exchange of Hong Kong Limited dated 16 March 2026.</p>\n<p>The agenda includes:\n1. Approval of the audited financial results for the year ended 31 December 2025.\n2. Consideration of a final dividend recommendation, if any.\n3. Discussion of other routine corporate matters.</p>\n<p>The board currently consists of three executive directors (Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang), one non-executive director (Mr. Robert Taylor Nelsen) and three independent non-executive directors (Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung).</p>\n<p>The company will release its FY2025 results after board approval, providing shareholders with detailed financial information and any dividend decision.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02552","symbol_name":"華領醫藥-B","start_time":0,"source_url":"","article_id":"1185329206","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185329206","pubTimestamp":1773650435,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hua Medicine-B (stock code: 02552) has scheduled a board meeting for 26 March 2026 (Thursday), according to a filing with The Stock Exchange of Hong Kong Limited dated 16 March 2026. The agenda...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02552":"华领医药-B"},"translate_title":"华领医药-B(02552)将于2026年3月26日审阅2025财年业绩及末期股息建议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02552":1},"content_text":"Hua Medicine-B (stock code: 02552) has scheduled a board meeting for 26 March 2026 (Thursday), according to a filing with The Stock Exchange of Hong Kong Limited dated 16 March 2026.\nThe agenda includes:\n1. Approval of the audited financial results for the year ended 31 December 2025.\n2. Consideration of a final dividend recommendation, if any.\n3. Discussion of other routine corporate matters.\nThe board currently consists of three executive directors (Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang), one non-executive director (Mr. Robert Taylor Nelsen) and three independent non-executive directors (Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung).\nThe company will release its FY2025 results after board approval, providing shareholders with detailed financial information and any dividend decision.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}